**At-a-Glance Summary
Excellence in CPA**

|  |  |
| --- | --- |
| **Candidate:** |  |
| **Requested Rank:** |  |

Note: Only include activities since your appointment or last promotion.

|  |  |  |  |
| --- | --- | --- | --- |
| **Category** |  | **Number** | **Amount** |
| **Honours and Career Awards** | [Name of Award] |  |  |
| **Peer-Reviewed Funding** | PI/co-PI |  |  |
| Co-Investigator, Collaborator |  |  |
| **Non-Reviewed Funding** |  |  |  |
| **Publications** | SRA/ co-SRA[Highlight any highly cited papers and/or journal impact factor] | [#] |
| PA |  |
| Co-author/Collaborator |  |
| **Invited Speaker**  | International |  |
|  | National |  |
| **Leadership Roles** | **International** |  |
|  | [Title] | [Organization] |  |
|  | **National** |  |
|  | [Title] | [Organization] |  |

|  |  |
| --- | --- |
| **Evidence of (National/ International) Impact** |  |
| **[Describe work]***For example***Biomarkers in breast ductal carcinoma in situ (DCIS) -** identified prognostic and predictive biomarkers in breast ductal carcinoma in situ (DCIS), a heterogeneous group of noninvasive breast cancer accounting for 20-25% of screen-detected breast cancer.  | **[Summary of accomplishments]*** validated the First Multigene Expression Assay in DCIS: Oncotype DX DCIS Recurrence Score (DS). The DS Score report incorporates tumor size and patient age, providing a refined 10-year risk of local recurrence of these tumours, allowing physicians to optimize treatment planning, such as when radiotherapy treatment is best given to these affected individuals.
* published 17 research and 26 review articles
* received $2M in peer-reviewed funding as co-investigator and $2.6M in industry funding. Lead pathologist or sole pathologist in these grants.
* presented work at the University of Minnesota, Oslo University Hospital, University of Manchester.
* changed practice and referenced in U.S. Centers for Medicare & Medicaid Services – Medicare Coverage Database.
 |